Cytokine Storm.
David C. Fajgenbaum,Carl H. June +1 more
Reads0
Chats0
TLDR
From the Department of Medicine, Division of Translational Medicine and Human Genetics, Center for Cytokine Storm Treatment and Laboratory, and the Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia.Abstract:
From the Department of Medicine, Division of Translational Medicine and Human Genetics, Center for Cytokine Storm Treatment and Laboratory (D.C.F.), and the Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy (C.H.J.), Perelman School of Medicine, University of Pennsylvania, Philadelphia. Address reprint requests to Dr. Fajgenbaum at davidfa@ pennmedicine . upenn . edu or to Dr. June at cjune@ upenn . edu.read more
Citations
More filters
Journal ArticleDOI
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
TL;DR: In this paper, the authors evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform trial, which used a Bayesian statistical model with predefined criteria for superiority, efficacy, equivalence or futility.
Journal ArticleDOI
Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19.
Aldo Bonaventura,Aldo Bonaventura,Alessandra Vecchié,Lorenzo Dagna,Kimberly Martinod,Dave L. Dixon,Benjamin W. Van Tassell,Francesco Dentali,Fabrizio Montecucco,Steffen Massberg,Marcel Levi,Antonio Abbate +11 more
TL;DR: In this paper, the authors proposed that SARS-CoV-2 infection induces a process known as immunothrombosis, in which activated neutrophils and monocytes interact with platelets and the coagulation cascade, leading to intravascular clot formation in small and larger vessels.
Journal ArticleDOI
COVID-19 and the human innate immune system.
TL;DR: In this article, a conceptual framework for the interaction of the human innate immune system with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was provided to link the clinical observations with experimental findings that have been made during the first year of the pandemic.
Journal ArticleDOI
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia.
Patrícia O. Guimarães,Daniel Quirk,Remo H. Furtado,Lilia N. Maia,José F. Saraiva,Murillo Oliveira Antunes,Roberto Kalil Filho,Vagner Madrini Junior,Alexandre de Matos Soeiro,Alexandre P. Tognon,Viviane C Veiga,Priscilla de Aquino Martins,Diogo D.F. Moia,Bruna S. Sampaio,Silvia R.L. Assis,Ronaldo V P Soares,Luciana P.A. Piano,Kleber Castilho,Roberta G.R.A.P. Momesso,Frederico Monfardini,Hélio Penna Guimarães,Dario Ponce de Leon,Majori Dulcine,Marcia Pinheiro,Levent M. Gunay,J. Jasper Deuring,Luiz Vicente Rizzo,Tamas Koncz,Otavio Berwanger +28 more
TL;DR: Among patients hospitalized with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure through day 28 than placebo, and the proportional odds of having a worse score on the eight-level ordinal scale with tofacinib, as compared with placebo.
Journal ArticleDOI
The signal pathways and treatment of cytokine storm in COVID-19.
TL;DR: In this paper, the authors discuss the latest developments in the immunopathological characteristics of COVID-19 and focus on CS including the current research status of the different cytokines involved, and discuss the induction, function, downstream signaling and existing and potential interventions for targeting these cytokines or related signal pathways.
References
More filters
Journal ArticleDOI
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Wen Zhang,Yan Zhao,Fengchun Zhang,Qian Wang,Tai-sheng Li,Zhengyin Liu,Jinglan Wang,Yan Qin,Xuan Zhang,Xiaowei Yan,Xiaofeng Zeng,Shuyang Zhang +11 more
TL;DR: The clinical and immunological characteristics of severe patients, and the current evidence and share the experience in anti-inflammation treatment of patients with severe COVID-19 that may have an impaired immune system are discussed.
Journal ArticleDOI
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu,David Marin,Pinaki P. Banerjee,Homer A. Macapinlac,Philip A. Thompson,Rafet Basar,Lucila Nassif Kerbauy,Bethany J Overman,Peter F. Thall,Mecit Kaplan,Vandana Nandivada,Indresh Kaur,Ana Karen Nunez Cortes,Kai Cao,May Daher,Chitra Hosing,Evan N. Cohen,Partow Kebriaei,Rohtesh S. Mehta,Sattva S. Neelapu,Yago Nieto,Michael Wang,William G. Wierda,Michael J. Keating,Richard E. Champlin,Elizabeth J. Shpall,Katayoun Rezvani +26 more
TL;DR: Among 11 patients with relapsed or refractory CD19-positive cancers, a majority had a response to treatment with CAR-NK cells without the development of major toxic effects.
Journal ArticleDOI
Interleukin-10 Therapy—Review of a New Approach
TL;DR: New insight is given into the immunobiology of IL-10 and it is suggested that the IL- 10/IL-10 receptor system may become a new therapeutic target.
Journal ArticleDOI
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Max S. Topp,Nicola Gökbuget,Anthony S. Stein,Gerhard Zugmaier,Susan O'Brien,Ralf C. Bargou,Hervé Dombret,Adele K. Fielding,Leonard T. Heffner,Richard A. Larson,Svenja Neumann,Robin Foà,Mark R. Litzow,Josep-Maria Ribera,Alessandro Rambaldi,Gary J. Schiller,Monika Brüggemann,Heinz A. Horst,Chris Holland,Catherine Jia,Tapan Maniar,Birgit Huber,Dirk Nagorsen,Stephen J. Forman,Hagop M. Kantarjian +24 more
TL;DR: Single-agent blinatumomab showed antileukaemia activity in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia characterised by negative prognostic factors.
Related Papers (5)
Dexamethasone in Hospitalized Patients with Covid-19
Peter Horby,Wei Shen Lim,Jonathan Emberson,M Mafham,Jennifer L Bell,Louise Linsell,Natalie Staplin,Christopher E. Brightling,Andrew Ustianowski,E Elmahi,B Prudon,Christopher A Green,Timothy Felton,David Chadwick,K Rege,C Fegan,Lucy C Chappell,Saul N. Faust,Thomas Jaki,Katie Jeffery,Alan A Montgomery,Kathryn M Rowan,Edmund Juszczak,J K Baillie,Richard Haynes,Martin J Landray +25 more
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more